Spots Global Cancer Trial Database for vhl
Every month we try and update this database with for vhl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00056199 | Hippel-Lindau D... | EYE001 | - | National Institutes of Health Clinical Center (CC) | |
| Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00089765 | Von Hippel-Lind... | Ranibizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma | NCT03108066 | VHL Gene Mutati... VHL VHL Syndrome VHL Gene Inacti... Von Hippel Von Hippel-Lind... Von Hippel's Di... Von Hippel-Lind... Clear Cell Rena... Clear Cell RCC ccRCC | PT2385 Tablets | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma | NCT06391879 | VHL Syndrome Renal Cell Carc... | Single cell seq... | 18 Years - 80 Years | Peking University First Hospital | |
| MyVHL: Patient Natural History Study | NCT03749980 | Von Hippel-Lind... Hereditary Leio... Birt-Hogg-Dube ... SDHB Gene Mutat... | - | VHL Alliance | ||
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Von Hippel-Lindau Disease Genetic Epidemiology Study | NCT00001803 | Von Hippel Lind... Kidney Neoplasm... | 13 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| TKI 258 in Von Hippel-Lindau Syndrome (VHL) | NCT01266070 | Von Hippel-Lind... | Dovitinib | 18 Years - | M.D. Anderson Cancer Center | |
| 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease | NCT00088374 | Hippel-Lindau D... Kidney Cancer | 17 allylamino-1... 18 FDG (Fludeox... [15-O] H2O EPL diluent | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma | NCT06391879 | VHL Syndrome Renal Cell Carc... | Single cell seq... | 18 Years - 80 Years | Peking University First Hospital | |
| Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease | NCT01015300 | Hemangioblastom... Von Hippel Lind... | Avastin | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | NCT03401788 | VHL - Von Hippe... VHL Gene Mutati... VHL Syndrome VHL Gene Inacti... VHL-Associated ... VHL-Associated ... | Belzutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| MyVHL: Patient Natural History Study | NCT03749980 | Von Hippel-Lind... Hereditary Leio... Birt-Hogg-Dube ... SDHB Gene Mutat... | - | VHL Alliance | ||
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Von Hippel-Lindau Disease Genetic Epidemiology Study | NCT00001803 | Von Hippel Lind... Kidney Neoplasm... | 13 Years - 100 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
